慢性肝病治療市場：依療法（抗病毒藥物）、疾病、通路及地區分類

Chronic Liver Diseases Therapeutics Market, By Treatment Type Antiviral Drugs, By Disease Type, By Distribution type, And By Region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa)

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，慢性肝病治療市場規模將達207.8億美元，2033年將達到434.1億美元。預計從2026年到2033年，該市場將以11.1%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	207.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.10%	2033年市場規模預測：	434.1億美元

肝臟是人體最大的固態器官，發揮多種功能，包括產生消化所需的膽汁、將食物轉化為能量，以及維持體內儲存所有細胞和生物活動所需營養素的適當水平。因此，如果肝臟功能異常，會導致許多嚴重，例如甲型、乙型和丙型肝炎、原發性肝硬化和腫瘤。肝功能障礙的主要原因包括肥胖、過度飲酒和遺傳性疾病。肝病的治療方案包括抗病毒藥物、免疫抑制劑、疫苗、免疫球蛋白、皮質類固醇、標靶治療和化療。此外，慢性肝病包括肝炎、自體免疫疾病、非酒精性脂肪性肝病（NAFLD）、癌症和遺傳性疾病。

市場動態

慢性肝病患者數量的不斷增加、旨在開發治療肝病新技術的研究和開發活動的活性化，以及市場上主要公司擴大採用併購、合作和聯合研究等非內部成長戰略，預計這些因素將推動全球慢性肝病治療市場在預測期內的成長。例如，2022年12月，專注於開發用於治療肥胖症和肝病的新型肽療法的臨床階段生物製藥公司Altimmune, Inc.宣布，其Pemvidutide治療非酒精性脂肪肝的24週（12週擴展期）試驗取得了積極的初步結果，顯示出顯著降低肝臟脂肪含量和減輕肝臟炎症的潛力。此外，2022 年 1 月，致力於開發治療脂肪肝新療法的臨床階段生物製藥公司 Madrigal Pharmaceuticals, Inc. 公佈了其最先進的臨床候選藥物 resmethirom 的安慰劑對照、雙盲 3 期 MAESTRO-NAFLD（非酒精性脂肪肝疾病）安全性試驗的初步臨床數據，結果令人滿意。

本研究的主要特點：

該研究揭示了各個細分市場的潛在商機，並說明了該市場中一系列有吸引力的投資提案。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，對全球慢性肝病治療市場的主要公司進行了概況介紹：公司概況、產品系列、主要亮點、財務表現和策略。
全球慢性肝病治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球慢性肝病治療市場中使用的各種策略矩陣來簡化決策過程。

公司簡介
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

第9章

參考
調查方法

簡介目錄

Product Code: CMI4047

Chronic Liver Diseases Therapeutics Market is estimated to be valued at USD 20.78 Bn in 2026 and is expected to reach USD 43.41 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 20.78 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.10%	2033 Value Projection:	USD 43.41 Bn

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
Antiviral drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution type (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Liver Diseases Therapeutics, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Astellas Pharma Inc
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution type
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2021€"2033 (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends

5. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2021€"2033 (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Hepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Non-alcoholic Fatty Liver Disease (NAFLD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)

6. Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2021€"2033 (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)

7. Global Chronic Liver Diseases Therapeutics Market, By Regions, 2021€"2033 (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Astellas Pharma Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol-Myers Squibb
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Gilead Sciences
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GlaxoSmithKline Plc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Merck & Co. Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Valeant Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Watson Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Theratechnologies Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alnylam Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Protagonist Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Dicerna Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Endo International
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Provectus Biopharmaceuticals Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- MAX BioPharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies